Breaking News

Monday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Travere Therapeutics price target lowered to $39 from $46 at Wedbush » 07:24 04/12/21 04/12 07:24 04/12/21 07:24 TVTX Travere Therapeutics $25.57 / +0.32 (+1.27%) Wedbush analyst Laura… Wedbush analyst Laura Chico lowered the firm's price target on Travere Therapeutics to $39 from $46 and keeps an Outperform rating on the shares. Chico sees limited impact from Q1 results as investors await more clarity on the sparsentan filing, the analyst says in a research note. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options TVTX Travere Therapeutics $25.57 / +0.32 (+1.27%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $25.57 / +0.32 (+1.27%) 03/02/21 BMO Capital Travere Therapeutics price target lowered to $43 from $48 at BMO Capital 02/16/21 Barclays Travere Therapeutics assumed with an Overweight at Barclays 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord TVTX Travere Therapeutics $25.57 / +0.32 (+1.27%) 03/01/21 Travere Therapeutics reports Q4 adjusted EPS ($2.20), consensus (47c) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M 12 Feb TVTX Travere Therapeutics $25.57 / +0.32 (+1.27%) 11/19/20 One new option listing and one option delisting on November 19th

Over a month ago
Recommendations	Travere Therapeutics price target lowered to $43 from $48 at BMO Capital » 09:31 03/02/21 03/02 09:31 03/02/21 09:31 TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) BMO Capital analyst Do… BMO Capital analyst Do Kim lowered the firm's price target on Travere Therapeutics to $43 from $48 but keeps an Outperform rating on the shares. The company's Q4 earnings miss was driven by the $97M acquisition charge for Orphan Technologies, the analyst tells investors in a research note. Kim adds that he sees the Sparsentan opportunity potentially expanding significantly, with positive IgAN PROTECT data in Q3, increasing his U.S peak sale estimate to $2.1B from $1.3B in FSGS alone. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 02/16/21 Barclays Travere Therapeutics assumed with an Overweight at Barclays 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 03/01/21 Travere Therapeutics reports Q4 adjusted EPS ($2.20), consensus (47c) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M 12 Feb TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 11/19/20 One new option listing and one option delisting on November 19th
Earnings	Travere Therapeutics reports Q4 adjusted EPS ($2.20), consensus (47c) » 16:14 03/01/21 03/01 16:14 03/01/21 16:14 TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) Reports Q4 revenue… Reports Q4 revenue $50.98M, consensus $51.66M. "In 2020, our organization executed on all of our key objectives despite the challenges of the ongoing pandemic. This resulted in achieving enrollment milestones in our pivotal studies of sparsentan in FSGS and IgAN at or ahead of schedule, diversifying our pipeline with the addition of TVT-058 and serving more patients than ever before with our approved products," said Eric Dube, chief executive officer of Travere Therapeutics. "Led by the interim readouts from our Phase 3 studies of sparsentan, we expect 2021 to be a pivotal year for Travere. We were very pleased to begin the year with the DUPLEX Study in FSGS achieving its pre-specified interim proteinuria endpoint. Reaching this clinical milestone positions us to engage with regulators in pursuit of submissions for accelerated approval as we continue efforts to prepare our organization for the future commercialization of sparsentan, if approved. We are also looking forward to the interim proteinuria assessment from the PROTECT Study in IgAN during the third quarter, which could potentially position us to ultimately deliver sparsentan as a new treatment standard in both FSGS and IgAN." ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events Options TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 02/16/21 Barclays Travere Therapeutics assumed with an Overweight at Barclays 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M 12 Feb 03/01/21 Travere Therapeutics - TVTX TVTX Travere Therapeutics $30.59 / -0.24 (-0.78%) 11/19/20 One new option listing and one option delisting on November 19th
Initiation	Travere Therapeutics assumed with an Overweight at Barclays » 06:21 02/16/21 02/16 06:21 02/16/21 06:21 TVTX Travere Therapeutics $26.33 / -1.34 (-4.84%) Barclays analyst Carter… Barclays analyst Carter Gould assumed coverage of Travere Therapeutics with an Overweight rating and $40 price target. Recent top-line sparsentan data from the DUPLEX trial was a "transformative event" for the company, representing a "de-risking milestone" in an initial glomerular disease, with encouraging read-through to a second, Gould tells investors in a research note. The analyst sees these data as supportive of approval in initial glomerular disease in 2022. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options TVTX Travere Therapeutics $26.33 / -1.34 (-4.84%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $26.33 / -1.34 (-4.84%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX Travere Therapeutics $26.33 / -1.34 (-4.84%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M 12 Feb TVTX Travere Therapeutics $26.33 / -1.34 (-4.84%) 11/19/20 One new option listing and one option delisting on November 19th
Syndicate	Travere Therapeutics 6.55M share Secondary priced at $26.75 » 06:28 02/12/21 02/12 06:28 02/12/21 06:28 TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) The deal size was… The deal size was increased to $175.2M in common stock from $150M in common stock. BofA, Jefferies and SVB Leerink acted as joint book running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Options TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M 12 Feb TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 11/19/20 One new option listing and one option delisting on November 19th

Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/12/21 02/12 04:55 02/12/21 04:55 ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) , AVRO Avrobio $16.85 / +0.05 (+0.30%) , BMRN BioMarin $86.80 / +1.37 (+1.60%) , DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) , FIXX Homology Medicines $13.75 / -0.24 (-1.72%) , FOLD Amicus $18.73 / -0.86 (-4.39%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $51.13 / -0.91 (-1.75%) , ORPH Orphazyme $12.79 / -0.01 (-0.08%) , ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) , PASG Passage Bio $21.44 / +1.465 (+7.33%) , PFE Pfizer $34.43 / -0.31 (-0.89%) , RARE Ultragenyx $162.86 / -4.38 (-2.62%) , SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) , SNY Sanofi $47.68 / -0.375 (-0.78%) , TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) , TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig SNY Sanofi $47.68 / -0.375 (-0.78%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 PFE Pfizer $34.43 / -0.31 (-0.89%) 02/10/21 BioNTech provides update on vaccine production at Marburg manufacturing site 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B PASG Passage Bio $21.44 / +1.465 (+7.33%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $12.79 / -0.01 (-0.08%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $51.13 / -0.91 (-1.75%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa 02/11/21 Amicus trading resumes 02/11/21 Amicus trading halted, news pending 02/08/21 Amicus announces preclinical Fabry disease gene therapy data FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $86.80 / +1.37 (+1.60%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $16.85 / +0.05 (+0.30%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $86.80 / +1.37 (+1.60%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 02/10/21 Fly Intel: Top five analyst upgrades 02/10/21 Cantor Fitzgerald Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $18.73 / -0.86 (-4.39%) 02/12/21 Cantor Fitzgerald Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald 02/12/21 JPMorgan Amicus downgraded to Neutral from Overweight at JPMorgan 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen IDRSF Idorsia $0.00 / + (+0.00%) 02/10/21 Morgan Stanley Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan NVTA Invitae $51.13 / -0.91 (-1.75%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $12.79 / -0.01 (-0.08%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $21.44 / +1.465 (+7.33%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.43 / -0.31 (-0.89%) 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/11/21 Piper Sandler Ultragenyx price target raised to $170 from $165 at Piper Sandler 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $47.68 / -0.375 (-0.78%) 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $47.68 / -0.375 (-0.78%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $162.86 / -4.38 (-2.62%) 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx backs FY21 revenue guidance range for Crysvita 02/11/21 Ultragenyx reports Q4 EPS (37c), consensus ($1.16) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.43 / -0.31 (-0.89%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $21.44 / +1.465 (+7.33%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.20 / -0.07 (-0.85%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $51.13 / -0.91 (-1.75%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $18.73 / -0.86 (-4.39%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FIXX Homology Medicines $13.75 / -0.24 (-1.72%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $86.80 / +1.37 (+1.60%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.36 / +0.01 (+0.30%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 12 Feb 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $47.68 / -0.375 (-0.78%) 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says PFE Pfizer $34.43 / -0.31 (-0.89%) 02/11/21 White House secures deals for additional 200M COVID-19 vaccine doses, CNBC says 02/11/21 Biden to announce deals for another 200M vaccine doses, Washington Post says 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says FOLD Amicus $18.73 / -0.86 (-4.39%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $86.80 / +1.37 (+1.60%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $47.68 / -0.375 (-0.78%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $39.79 / +1.04 (+2.68%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.43 / -0.31 (-0.89%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $21.44 / +1.465 (+7.33%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $12.79 / -0.01 (-0.08%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $51.13 / -0.91 (-1.75%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Fly Intel: After-Hours Movers 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $69.32 / -4.115 (-5.60%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $86.80 / +1.37 (+1.60%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $16.85 / +0.05 (+0.30%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/16/21 Abeona Clinical Investigator Webinar 02/25/21 10th Annual Global Healthcare Virtual Conference 03/02/21 41st Annual Healthcare Virtual Conference 03/03/21 2021 London Global Healthcare Virtual Conference 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $27.75 / -1.23 (-4.24%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.54 / +0.01 (+0.06%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.43 / -0.31 (-0.89%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $21.44 / +1.465 (+7.33%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $51.13 / -0.91 (-1.75%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $18.73 / -0.86 (-4.39%) 02/11/21 Amicus put volume heavy and directionally bearish 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $86.80 / +1.37 (+1.60%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/11/21 02/11 04:55 02/11/21 04:55 ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) , AVRO Avrobio $16.80 / -0.88 (-4.98%) , BMRN BioMarin $85.43 / -0.31 (-0.36%) , DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) , FIXX Homology Medicines $14.00 / -0.36 (-2.51%) , FOLD Amicus $19.59 / +0.41 (+2.14%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $51.98 / -0.57 (-1.08%) , ORPH Orphazyme $12.79 / -0.28 (-2.14%) , ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) , PASG Passage Bio $19.87 / -0.22 (-1.10%) , PFE Pfizer $34.74 / -0.22 (-0.63%) , RARE Ultragenyx $167.17 / -0.19 (-0.11%) , SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) , SNY Sanofi $48.06 / -0.815 (-1.67%) , TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) , TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 02/10/21 Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig SNY Sanofi $48.06 / -0.815 (-1.67%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $167.17 / -0.19 (-0.11%) 02/10/21 Ultragenyx down 2% in early trading as FAERS report on Dojolvi circulated 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 PFE Pfizer $34.74 / -0.22 (-0.63%) 02/10/21 BioNTech provides update on vaccine production at Marburg manufacturing site 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B PASG Passage Bio $19.87 / -0.22 (-1.10%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $12.79 / -0.28 (-2.14%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $51.98 / -0.57 (-1.08%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.59 / +0.41 (+2.14%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $85.43 / -0.31 (-0.36%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $16.80 / -0.88 (-4.98%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $85.43 / -0.31 (-0.36%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 02/10/21 Fly Intel: Top five analyst upgrades 02/10/21 Cantor Fitzgerald Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.59 / +0.41 (+2.14%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/10/21 Morgan Stanley Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan NVTA Invitae $51.98 / -0.57 (-1.08%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $12.79 / -0.28 (-2.14%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $19.87 / -0.22 (-1.10%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.74 / -0.22 (-0.63%) 02/10/21 KeyBanc Maravai Lifesciences price target raised to $39 from $33 at KeyBanc 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink RARE Ultragenyx $167.17 / -0.19 (-0.11%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.06 / -0.815 (-1.67%) 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.06 / -0.815 (-1.67%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $167.17 / -0.19 (-0.11%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.74 / -0.22 (-0.63%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $19.87 / -0.22 (-1.10%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.27 / -0.09 (-1.08%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $51.98 / -0.57 (-1.08%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.59 / +0.41 (+2.14%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) FIXX Homology Medicines $14.00 / -0.36 (-2.51%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $85.43 / -0.31 (-0.36%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.35 / +0.025 (+0.75%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 12 Feb 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.06 / -0.815 (-1.67%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.74 / -0.22 (-0.63%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.59 / +0.41 (+2.14%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $85.43 / -0.31 (-0.36%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.06 / -0.815 (-1.67%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.75 / +0.48 (+1.25%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.74 / -0.22 (-0.63%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $19.87 / -0.22 (-1.10%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $12.79 / -0.28 (-2.14%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $51.98 / -0.57 (-1.08%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.59 / +0.41 (+2.14%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $73.36 / +0.38 (+0.52%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $85.43 / -0.31 (-0.36%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $16.80 / -0.88 (-4.98%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/16/21 Abeona Clinical Investigator Webinar 03/02/21 41st Annual Healthcare Virtual Conference 03/03/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $28.98 / -0.93 (-3.11%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.53 / -0.195 (-1.10%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.74 / -0.22 (-0.63%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $19.87 / -0.22 (-1.10%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $51.98 / -0.57 (-1.08%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.59 / +0.41 (+2.14%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $85.43 / -0.31 (-0.36%) 09/18/20 BioMarin call volume above normal and directionally bullish
Syndicate	Travere Therapeutics annonces $150M common stock offering » 16:03 02/10/21 02/10 16:03 02/10/21 16:03 TVTX Travere Therapeutics $29.06 / -0.85 (-2.84%) Travere Therapeutics… Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $150M of its common stock. BofA Securities, Jefferies and SVB Leerink are acting as the joint book-running managers for the offering. ShowHide Related Items >><< Company News Street Research Earnings Options TVTX Travere Therapeutics $29.06 / -0.85 (-2.84%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TVTX Travere Therapeutics $29.06 / -0.85 (-2.84%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX Travere Therapeutics $29.06 / -0.85 (-2.84%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M TVTX Travere Therapeutics $29.06 / -0.85 (-2.84%) 11/19/20 One new option listing and one option delisting on November 19th
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/10/21 02/10 04:55 02/10/21 04:55 ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) , AVRO Avrobio $17.68 / -1.62 (-8.39%) , BMRN BioMarin $85.63 / -0.55 (-0.64%) , DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) , FIXX Homology Medicines $14.38 / -0.39 (-2.64%) , FOLD Amicus $19.18 / -0.7 (-3.52%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $52.55 / +1.74 (+3.42%) , ORPH Orphazyme $13.07 / + (+0.00%) , ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) , PASG Passage Bio $20.12 / -0.57 (-2.75%) , PFE Pfizer $34.96 / +0.14 (+0.40%) , RARE Ultragenyx $167.72 / +1.9 (+1.15%) , SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) , SNY Sanofi $48.87 / +0.275 (+0.57%) , TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) , TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $48.87 / +0.275 (+0.57%) 02/09/21 Regeneron, Sanofi say FDA approves PD-1 inhibitor Libtayo 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $167.72 / +1.9 (+1.15%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M PFE Pfizer $34.96 / +0.14 (+0.40%) 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses PASG Passage Bio $20.12 / -0.57 (-2.75%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 02/09/21 Orchard Therapeutics announces interim data for OTL-203 in Hurler Syndrome 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN ORPH Orphazyme $13.07 / + (+0.00%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $52.55 / +1.74 (+3.42%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.18 / -0.7 (-3.52%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $85.63 / -0.55 (-0.64%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $17.68 / -1.62 (-8.39%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $85.63 / -0.55 (-0.64%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright 11/10/20 Goldman Sachs Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs 11/06/20 H.C. Wainwright Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.18 / -0.7 (-3.52%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan 10/28/20 Deutsche Bank Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank NVTA Invitae $52.55 / +1.74 (+3.42%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $13.07 / + (+0.00%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $20.12 / -0.57 (-2.75%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.96 / +0.14 (+0.40%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler RARE Ultragenyx $167.72 / +1.9 (+1.15%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.87 / +0.275 (+0.57%) 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.87 / +0.275 (+0.57%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $167.72 / +1.9 (+1.15%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.96 / +0.14 (+0.40%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $20.12 / -0.57 (-2.75%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $8.32 / +1.055 (+14.52%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $52.55 / +1.74 (+3.42%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.18 / -0.7 (-3.52%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) FIXX Homology Medicines $14.38 / -0.39 (-2.64%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) 08/10/20 Homology Medicines reports Q2 EPS (78c), consensus (76c) DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $85.63 / -0.55 (-0.64%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.32 / -0.05 (-1.48%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.87 / +0.275 (+0.57%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.96 / +0.14 (+0.40%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.18 / -0.7 (-3.52%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $85.63 / -0.55 (-0.64%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.87 / +0.275 (+0.57%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.27 / -0.4 (-1.03%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.96 / +0.14 (+0.40%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $20.12 / -0.57 (-2.75%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $13.07 / + (+0.00%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $52.55 / +1.74 (+3.42%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.18 / -0.7 (-3.52%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $72.98 / -3.57 (-4.66%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $85.63 / -0.55 (-0.64%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $17.68 / -1.62 (-8.39%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/12/21 17th Annual Virtual WORLDSymposium 2021 02/16/21 Abeona Clinical Investigator Webinar 03/02/21 41st Annual Healthcare Virtual Conference 03/03/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $29.91 / -1.09 (-3.52%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.73 / +0.315 (+1.81%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.96 / +0.14 (+0.40%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $20.12 / -0.57 (-2.75%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $52.55 / +1.74 (+3.42%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.18 / -0.7 (-3.52%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $85.63 / -0.55 (-0.64%) 09/18/20 BioMarin call volume above normal and directionally bullish
Conference/Events	Lysosomal Disease Network to hold a virtual symposium » 04:55 02/09/21 02/09 04:55 02/09/21 04:55 ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) , AVRO Avrobio $19.30 / +2.17 (+12.67%) , BMRN BioMarin $86.19 / +1.18 (+1.39%) , DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) , FIXX Homology Medicines $14.76 / +0.92 (+6.65%) , FOLD Amicus $19.88 / -0.21 (-1.05%) , IDRSF Idorsia $0.00 / + (+0.00%) , NVTA Invitae $50.81 / +1.19 (+2.40%) , ORPH Orphazyme $13.07 / +0.57 (+4.56%) , ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) , PASG Passage Bio $20.69 / -0.86 (-3.99%) , PFE Pfizer $34.82 / -0.1 (-0.29%) , RARE Ultragenyx $166.04 / +4.28 (+2.65%) , SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) , SNY Sanofi $48.60 / +0.4 (+0.83%) , TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) , TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 17th Annual Virtual… 17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options TVTX TAK SNY SGTX RARE PFE PASG ORTX ORPH NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/28/21 Takeda presents results for mobocertinib in patients with EGFR Exon20 insertion 01/21/21 Moderna announces 1st participant dosed in Japan study of Moderna COVID vaccine 12/18/20 Takeda confirms FDA approval of sNDA for Iclusig 12/16/20 Takeda Pharma, Prime Therapeutics sign arrangement for Hemophilia A treatment SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Sanofi presents amended protocols in fitusiran clinical studies 01/27/21 Sanofi's priority is to continue to develop two Covid vaccine candidates 01/27/21 Sanofi to provide support to BioNTech in manufacturing Covid vaccine 01/25/21 Nanobiotix to partner with Sanofi on gene therapy pipeline SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/17/20 Sigilon Therapeutics receives Orphan Drug designation for SIG-005 12/14/20 Sigilon Therapeutics gets FDA orphan drug designation for Arpe-19 RARE Ultragenyx $166.04 / +4.28 (+2.65%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M PFE Pfizer $34.82 / -0.1 (-0.29%) 02/08/21 Longevity announces 4D trial collaboration with Pfizer and Merck KGaA 02/05/21 Pfizer confirms U.S. patent term extension for IBRANCE until March, 2027 02/02/21 Pfizer sees FY21 revenue from BNT162b2 approximately $15B 02/01/21 BioNTech, Pfizer boost 2021 Covid vaccine output to 2B from 1.3B doses PASG Passage Bio $20.69 / -0.86 (-3.99%) 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 01/11/21 Passage Bio says PBGM01 entering clinic to study safety, efficacy 01/11/21 Passage Bio announces corporate outlook ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 02/05/21 Orchard Therapeutics announces $150M strategic financing 01/29/21 Orchard Therapeutics appoints Braden Parker as CCO 01/19/21 Orchard Therapeutics enters exclusive agreements with GenPharm Services, GEN 01/14/21 Orchard Therapeutics granted RMAT designation for OTL-200 ORPH Orphazyme $13.07 / +0.57 (+4.56%) 12/31/20 CytRx says Orphazyme's arimoclomol PDUFA target date extended to June 17, 2021 12/07/20 CytRx announces Orphazyme U.S. expansion ahead of potential arimoclomol approval 11/11/20 CytRx says Orphazyme submited MAA to EMA for arimoclomol for NPC treatment 11/09/20 Orphazyme submits arimoclomol MAA to EMA NVTA Invitae $50.81 / +1.19 (+2.40%) 01/13/21 Pacific Biosciences, Invitae to develop genome sequencing platform 01/11/21 Invitae falls -10.2% 12/17/20 Invitae falls -7.4% 12/17/20 Invitae introduces routine exome reanalysis FOLD Amicus $19.88 / -0.21 (-1.05%) 02/08/21 Amicus announces preclinical Fabry disease gene therapy data 02/08/21 Amicus reports 'positive' initial clinical data for CLN3 program 01/11/21 Amicus announces 2021 upcoming milestones 01/11/21 Amicus announces 2021 strategic priorities FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 02/08/21 Homology reports first presentation of data from IND-enabling studies of HMI-203 01/12/21 Pfizer invests $120M in four clinical-stage biotech companies 01/06/21 Homology Medicines announces plans for three clinical programs in 2021 11/19/20 Homology Medicines jumps 3% to $10.03 after passive stake disclosed by Pfizer DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 01/20/21 Denali Therapeutics CFO sells 50K shares of common stock 01/11/21 Denali Therapeutics appoints Nancy Thornberry to board of directors 01/08/21 Denali plans to file IND or CTA for DNL919 in late 2021/early 2022 01/08/21 Denali Therapeutics plans to file IND or CTA for DNL593 in late 2021 BMRN BioMarin $86.19 / +1.18 (+1.39%) 01/10/21 BioMarin announces topline results from ongoing global Phase 3 GENEr8-1 study 12/21/20 BioMarin reports results of Phase 3 extension study of vosoritide 11/17/20 BioMarin and Deep Genomics enter into preclinical collaboration 11/09/20 BioMarin expands clinical program for vosoritide with new studies AVRO Avrobio $19.30 / +2.17 (+12.67%) 02/08/21 Avrobio reports 100% kidney substrate reduction in first patient in FAB-GTi 01/19/21 Avrobio appoints Diana Escolar as CMO 11/17/20 Avrobio announces new data in clinical programs 10/05/20 Avrobio to collaborate with University of Manchester for MPS II therapy ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 01/25/21 Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops ABEO AVRO BMRN DNLI FIXX FOLD IDRSF NVTA ORPH ORTX PASG PFE RARE SGTX SNY TAK TVTX ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/18/20 Mizuho Avrobio price target raised to $43 from $35 at Mizuho 11/11/20 Berenberg Biotechnology companies initiated at Berenberg 11/11/20 Berenberg Avrobio initiated with a Buy at Berenberg 03/31/20 H.C. Wainwright Avrobio downgraded to Neutral from Buy at H.C. Wainwright BMRN BioMarin $86.19 / +1.18 (+1.39%) 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list 01/11/21 Baird BioMarin price target raised to $110 from $100 at Baird 12/21/20 Piper Sandler BioMarin data today should ease approvability concerns, says Piper Sandler 12/17/20 JPMorgan BioMarin remains 'highest conviction name' at JPMorgan DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 11/11/20 JPMorgan Denali Therapeutics price target raised to $65 from $45 at JPMorgan 11/11/20 H.C. Wainwright Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright 11/10/20 Goldman Sachs Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs 11/06/20 H.C. Wainwright Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 12/14/20 H.C. Wainwright Homology Medicines transferred with Buy, $30 target at H.C. Wainwright 11/08/20 Oppenheimer Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer 08/11/20 Oppenheimer Homology Medicines price target lowered to $27 from $32 at Oppenheimer 08/11/20 H.C. Wainwright Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright FOLD Amicus $19.88 / -0.21 (-1.05%) 01/22/21 JPMorgan Amicus remains top idea into 'meaningful catalyst' at JPMorgan 01/04/21 Cowen Amicus could move 30%-40% on Pompe study data, says Cowen 12/28/20 Cantor Fitzgerald Amicus assumed with an Overweight at Cantor Fitzgerald 12/14/20 JPMorgan JPMorgan boosts Amicus target to $29, adds to Analyst Focus List IDRSF Idorsia $0.00 / + (+0.00%) 02/08/21 JPMorgan Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan 10/29/20 Morgan Stanley Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley 10/28/20 JPMorgan Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan 10/28/20 Deutsche Bank Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank NVTA Invitae $50.81 / +1.19 (+2.40%) 02/01/21 Oppenheimer Invitae downgraded to Perform on valuation at Oppenheimer 02/01/21 Oppenheimer Invitae downgraded to Perform from Outperform at Oppenheimer 11/06/20 Ladenburg Invitae downgraded to Neutral on valuation at Ladenburg 11/06/20 Ladenburg Invitae downgraded to Neutral from Buy at Ladenburg ORPH Orphazyme $13.07 / +0.57 (+4.56%) 10/26/20 Guggenheim Orphazyme initiated with a Buy at Guggenheim 10/26/20 BofA Orphazyme initiated with a Buy at BofA 10/26/20 BofA Orphazyme initiated with a Buy at BofA ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 01/07/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 01/06/21 Cantor Fitzgerald Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald 09/14/20 Oppenheimer Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer 09/10/20 SMBC Nikko Orchard Therapeutics initiated with an Outperform at SMBC Nikko PASG Passage Bio $20.69 / -0.86 (-3.99%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PFE Pfizer $34.82 / -0.1 (-0.29%) 02/04/21 DZ Bank Pfizer upgraded to Buy from Hold at DZ Bank 02/03/21 Mizuho Pfizer price target lowered to $42 from $44 at Mizuho 02/01/21 SVB Leerink Moderna price target raised to $80 from $69 at SVB Leerink 01/29/21 Piper Sandler Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler RARE Ultragenyx $166.04 / +4.28 (+2.65%) 01/25/21 Credit Suisse Ultragenyx price target raised to $99 from $64 at Credit Suisse 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/29/20 Barclays Sigilon Therapeutics initiated with an Overweight at Barclays 12/29/20 Morgan Stanley Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley 12/29/20 Jefferies Sigilon Therapeutics initiated with a Buy at Jefferies SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS 01/15/21 Deutsche Bank Sanofi initiated with a Sell at Deutsche Bank 01/08/21 Morgan Stanley Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/29/21 Morgan Stanley Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout 12/29/20 Needham Needham names Phathom Pharmaceuticals Top Pick for 2021 12/15/20 Needham Phathom Pharmaceuticals price target raised to $55 from $45 at Needham 06/18/20 RBC Capital Neurocrine price target raised to $135 from $116 at RBC Capital TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/03/21 Travere Therapeutics price target raised to $48 from $33 at BMO Capital 02/03/21 Canaccord Travere Therapeutics price target raised to $51 from $28 at Canaccord 11/23/20 Evercore ISI Travere Therapeutics initiated with an Outperform at Evercore ISI TVTX SNY RARE PFE PASG ORTX NVTA FOLD FIXX DNLI BMRN AVRO ABEO TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M 01/11/21 Travere Therapeutics sees Q4 revenue $51M, consensus $51.33M SNY Sanofi $48.60 / +0.4 (+0.83%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year RARE Ultragenyx $166.04 / +4.28 (+2.65%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) PFE Pfizer $34.82 / -0.1 (-0.29%) 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer raises FY21 adjusted EPS view to $3.10-$3.20, consensus $3.19 02/02/21 Pfizer reports Q4 adjusted EPS 42c, consensus 48c 02/01/21 Notable companies reporting before tomorrow's open PASG Passage Bio $20.69 / -0.86 (-3.99%) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 08/13/20 Passage Bio reports Q2 EPS (60c), consensus (57c) ORTX Orchard Therapeutics $7.27 / -0.085 (-1.16%) 11/03/20 Orchard Therapeutics reports Q3 EPS (20c), consensus (46c) NVTA Invitae $50.81 / +1.19 (+2.40%) 01/11/21 Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M 01/11/21 Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M 11/05/20 Invitae reports Q3 non-GAAP EPS (62c), consensus (66c) FOLD Amicus $19.88 / -0.21 (-1.05%) 11/05/20 Amicus reports Q3 EPS (25c), consensus (22c) 08/10/20 Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M 08/10/20 Amicus reports Q2 EPS (20c), consensus (26c) FIXX Homology Medicines $14.76 / +0.92 (+6.65%) 11/09/20 Homology Medicines reports Q 3EPS (62c), consensus (80c) 08/10/20 Homology Medicines reports Q2 EPS (78c), consensus (76c) DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 11/05/20 Denali Therapeutics reports Q3 EPS (54c) vs. (48c) last year BMRN BioMarin $86.19 / +1.18 (+1.39%) 11/05/20 BioMarin sees FY20 revenue $1.81B-$1.87B, consensus $1.86B 11/05/20 BioMarin reports Q3 adjusted EPS $4.01, consensus $1.29 AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/05/20 Avrobio reports Q3 EPS ($1.01), consensus (81c) ABEO Abeona Therapeutics $3.37 / +0.78 (+30.12%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 22 Jan 22 Jan 04 Dec 20 Nov 29 Oct 29 Sep 02 Apr 28 Feb 13 Feb TAK SNY PFE FOLD BMRN TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/01/20 NIH says not enough evidence to recommend convalescent plasma, Bloomberg reports 09/01/20 NIH panel says data fail to back EUA for convalescent plasma, Bloomberg reports 08/19/20 Takeda plans to sell OTC drug unit to Blackstone for $2.3B, Nikkei reports SNY Sanofi $48.60 / +0.4 (+0.83%) 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports PFE Pfizer $34.82 / -0.1 (-0.29%) 02/05/21 Pfizer withdraws EUA application for COVID-19 vaccine in India, Reuters reports 01/28/21 Pfizer study finds vaccine works against U.K., South Africa variants, WSJ says 01/26/21 Pfizer sees ability to deliver vaccine faster than expected, Bloomberg reports 01/25/21 Italy issues warning letter to Pfizer due to COVID vaccine delays, Reuters says FOLD Amicus $19.88 / -0.21 (-1.05%) 10/16/20 Amicus 'a name to watch' if Vertex seeks M&A, Dealreporter says BMRN BioMarin $86.19 / +1.18 (+1.39%) 02/02/21 Amicus, BioMarin speculated by Dealreporter as possible Vertex targets TAK SNY SGTX PFE PASG ORPH NVTA FOLD DNLI BMRN AVRO TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 08/24/20 Fly Intel: Wall Street's top stories for Monday 08/24/20 Fly Intel: Wall Street's top stories at midday 08/24/20 Plasma producers spike after EUA issued for convalescent plasma to treat COVID 08/24/20 Fly Intel: Pre-market Movers SNY Sanofi $48.60 / +0.4 (+0.83%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday SGTX Sigilon Therapeutics $38.70 / +4.52 (+13.22%) 12/06/20 Opening Day: Kinnate Biopharma soars in trading debut 11/29/20 Opening Day: Russian online retailer raises $990M in U.S. IPO 11/22/20 Opening Day: Yatsen soars in debut, raises $617M in U.S. IPO 11/15/20 Opening Day: DoorDash files to go public as Airbnb delays IPO PFE Pfizer $34.82 / -0.1 (-0.29%) 02/02/21 Fly Intel: Wall Street's top stories for Tuesday 02/02/21 Fly Intel: Wall Street's top stories at midday 01/29/21 Fly Intel: Wall Street's top stories for Friday 01/29/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $20.69 / -0.86 (-3.99%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday ORPH Orphazyme $13.07 / +0.57 (+4.56%) 10/04/20 Opening Day: Palantir, Asana go public via direct listings 09/27/20 Opening Day: GoodRx rises over 50% in market debut 09/20/20 Opening Day: Snowflake shares double in biggest software IPO ever 09/13/20 Opening Day: More new SPACs debut amid growing popularity NVTA Invitae $50.81 / +1.19 (+2.40%) 01/20/21 Fly Intel: After-Hours Movers FOLD Amicus $19.88 / -0.21 (-1.05%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 11/11/20 Hilton upgrade, AIG downgrade among today's top calls on Wall Street DNLI Denali Therapeutics $76.96 / +6.45 (+9.15%) 09/28/20 Fly Intel: After-Hours Movers BMRN BioMarin $86.19 / +1.18 (+1.39%) 08/20/20 Shake Shack upgrade, BioMarin downgrades among today's top calls on Wall Street AVRO Avrobio $19.30 / +2.17 (+12.67%) 11/20/20 Fly Intel: Wall Street's top stories for Friday 11/20/20 Fly Intel: Wall Street's top stories at midday 11/20/20 Fly Intel: Pre-market Movers 11/19/20 Fly Intel: After-Hours Movers 02/22/21 Healthcare 02/12/21 17th Annual Virtual WORLDSymposium 2021 02/16/21 Abeona Clinical Investigator Webinar 03/02/21 41st Annual Healthcare Virtual Conference 03/03/21 2021 London Global Healthcare Virtual Conference 02/11/21 Ultragenyx - RARE 02/17/21 Invitae - NVTA 02/25/21 BioMarin - BMRN 05/18/21 PDUFA Date for Avalglucosidase Alfa 06/17/21 PDUFA Date for Arimoclomol 08/20/21 PDUFA Date for Vosoritide 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 02/22/21 Avrobio TVTX TAK PFE PASG NVTA FOLD BMRN TVTX Travere Therapeutics $31.00 / -0.55 (-1.74%) 11/19/20 One new option listing and one option delisting on November 19th TAK Takeda Pharmaceutical $17.42 / +0.235 (+1.37%) 01/22/21 Takeda Pharmaceutical call volume above normal and directionally bullish PFE Pfizer $34.82 / -0.1 (-0.29%) 01/29/21 Unusually active option classes on open January 29th 01/25/21 Pfizer call volume above normal and directionally bullish 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th PASG Passage Bio $20.69 / -0.86 (-3.99%) 12/09/20 Nine new option listings on December 9th NVTA Invitae $50.81 / +1.19 (+2.40%) 12/07/20 Invitae call volume above normal and directionally bullish 11/12/20 Invitae call volume above normal and directionally bullish 11/11/20 Invitae call volume above normal and directionally bullish 10/07/20 Invitae call volume above normal and directionally bullish FOLD Amicus $19.88 / -0.21 (-1.05%) 02/03/21 Amicus call volume above normal and directionally bullish BMRN BioMarin $86.19 / +1.18 (+1.39%) 09/18/20 BioMarin call volume above normal and directionally bullish

On The Fly

News and insights, exclusive to thefly.com

09:53	Fly Intel: Top five analyst initiations»
09:53	Fly Intel: Top five analyst downgrades»
09:53	Fly Intel: Top five analyst upgrades»
05:33	Coinbase initiated with a Buy at BTIG»
05:03	Moderna price target raised to $234 from $208 at Piper Sandler»

View all On The Fly Stories »

Upcoming
Events (10)

AKYA	Akoya Biosciences - AKYA
BMEA	Biomea Fusion - BMEA
NPCE	NeuroPace - NPCE
COO	Cooper Companies - COO
VNRX	VolitionRx - VNRX
VERI	Veritone - VERI
	Scrap, Direct Reduced Iron & Mini-Mills 2021
HD ...	7th Annual Virtual Retail Round-Up
	Annual Clinical Genetics Virtual Meeting of ACMG
	KeyBank Executive Virtual Roundtable

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals for your search.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial